BRPI0920240A2 - formulação de adjuvante de combinação - Google Patents

formulação de adjuvante de combinação

Info

Publication number
BRPI0920240A2
BRPI0920240A2 BRPI0920240A BRPI0920240A BRPI0920240A2 BR PI0920240 A2 BRPI0920240 A2 BR PI0920240A2 BR PI0920240 A BRPI0920240 A BR PI0920240A BR PI0920240 A BRPI0920240 A BR PI0920240A BR PI0920240 A2 BRPI0920240 A2 BR PI0920240A2
Authority
BR
Brazil
Prior art keywords
adjuvant formulation
combination adjuvant
combination
formulation
adjuvant
Prior art date
Application number
BRPI0920240A
Other languages
English (en)
Inventor
Andrew Potter
George Mutwiri
Jason Kindrachuck
Jennifer Kovacs-Nolan
Lorne Babiuk
Melissa Elliott
Mi-Na Kweon
Robert Hancock
Scott Halperin
Song Lee
Sylvia Van Drunen Littel-Van Den Hurk
Volker Gerdts
Original Assignee
Univ Dalhousie
Internat Vaccine Inst
Univ British Columbia
Univ Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dalhousie, Internat Vaccine Inst, Univ British Columbia, Univ Saskatchewan filed Critical Univ Dalhousie
Publication of BRPI0920240A2 publication Critical patent/BRPI0920240A2/pt
Publication of BRPI0920240B1 publication Critical patent/BRPI0920240B1/pt
Publication of BRPI0920240B8 publication Critical patent/BRPI0920240B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0920240A 2008-10-16 2009-10-15 composição adjuvante BRPI0920240B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19622608P 2008-10-16 2008-10-16
US61/196.226 2008-10-16
PCT/CA2009/001463 WO2010043039A1 (en) 2008-10-16 2009-10-15 Combination adjuvant formulation

Publications (3)

Publication Number Publication Date
BRPI0920240A2 true BRPI0920240A2 (pt) 2016-08-02
BRPI0920240B1 BRPI0920240B1 (pt) 2021-01-19
BRPI0920240B8 BRPI0920240B8 (pt) 2021-05-25

Family

ID=42106164

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920240A BRPI0920240B8 (pt) 2008-10-16 2009-10-15 composição adjuvante

Country Status (9)

Country Link
US (2) US9061001B2 (pt)
EP (1) EP2344522B1 (pt)
AU (1) AU2009304552B2 (pt)
BR (1) BRPI0920240B8 (pt)
CA (1) CA2737352C (pt)
DK (1) DK2344522T3 (pt)
HU (1) HUE028497T2 (pt)
NZ (2) NZ601345A (pt)
WO (1) WO2010043039A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737352C (en) * 2008-10-16 2017-06-27 University Of Saskatchewan Combination adjuvant formulation
WO2012015979A2 (en) * 2010-07-27 2012-02-02 The Regents Of The University Of California Hmgb1-derived peptides enhance immune response to antigens
WO2013034982A2 (en) * 2011-09-09 2013-03-14 The University Of British Columbia Immunomodulatory peptides for treatment of progressive neurodegenerative diseases
WO2014008406A2 (en) 2012-07-05 2014-01-09 Children's Medical Center Corporation The bacterial biofilm matrix as a platform for protein delivery
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3231436B1 (en) 2014-12-08 2020-03-11 Gi Biome Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
WO2017011919A1 (en) * 2015-07-22 2017-01-26 University Of Saskatchewan Mycoplasma vaccines and uses thereof
WO2017087844A1 (en) * 2015-11-18 2017-05-26 University Of Maryland, College Park Polyphosphazenes, methods of making, and uses thereof
TW201731525A (zh) * 2015-11-25 2017-09-16 薩斯喀徹溫大學 治療、預防及診斷豬流行性下痢病毒感染之方法
WO2017172929A1 (en) * 2016-03-29 2017-10-05 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
US10624947B2 (en) 2016-03-29 2020-04-21 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
US10858483B2 (en) 2016-07-06 2020-12-08 University Of Maryland, College Park Polyphosphazene polyelectrolytes and uses thereof
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11793858B2 (en) 2018-04-13 2023-10-24 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
WO2020172757A1 (en) * 2019-02-28 2020-09-03 University Of Saskatchewan Lawsonia intracellularis compositions and methods of using the same
CA3226187A1 (en) 2021-07-16 2023-01-19 The Board Of Trustees Of The University Of Illinois Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985354A (en) 1995-06-07 1999-11-16 Brown University Research Foundation Preparation of multiwall polymeric microcapsules from hydrophilic polymers
US5053451A (en) 1990-01-19 1991-10-01 The Pennsylvania Research Corporation Ionically cross-linkable polyphosphazene: poly(bis(carboxylatophenoxy) phosphazene) and its hydrogels and membranes
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5855895A (en) 1995-06-07 1999-01-05 Virus Research Institute Polyphosphazene polyelectrolyte immunoadjuvants
AU713040B2 (en) * 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5891444A (en) * 1995-06-07 1999-04-06 Virus Research Institute, Inc. HIV-1 prophylactic composition and method
US5807757A (en) 1996-07-02 1998-09-15 Virus Research Institute, Inc. Preparation of ionically cross-linked polyphosphazene microspheresy by coacervation
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US5760271A (en) * 1997-08-18 1998-06-02 Virus Research Institute, Inc. Production of polyorganophosphazenes
US6207171B1 (en) 1998-03-27 2001-03-27 Avant Immunotherapeutics, Inc. Polyphosphazene microspheres
ES2284247T3 (es) * 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
US6261573B1 (en) 1998-10-30 2001-07-17 Avant Immunotherapeutics, Inc. Immunoadjuvants
US7169395B1 (en) * 1998-12-17 2007-01-30 Sanofi Pasteur Limited Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
WO2001015727A2 (en) 1999-09-02 2001-03-08 Antigenics Inc. Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
ES2265980T5 (es) 1999-09-27 2010-12-28 Coley Pharmaceutical Group, Inc. Metodos relacionados con interferón inducido por ácidos nucleicos inmunoestimuladores.
DK1297110T3 (da) * 2000-06-23 2009-11-16 Intervet Int Bv Attenueret bovin respiratorisk syncytialvirus
DK1446162T3 (da) 2001-08-17 2008-12-08 Coley Pharm Gmbh Kombinationsmotiv-immunstimulatoriske oligonukleotider med forbedret aktivitet
WO2003030934A2 (en) * 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
JP2005519990A (ja) * 2001-10-12 2005-07-07 ユニバーシティ オブ アイオワ リサーチ ファウンデーション イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
US20040161470A1 (en) * 2002-11-22 2004-08-19 Alexander Andrianov Preparation of polyphosphazene microspheres
EP1697511A4 (en) * 2003-12-11 2007-11-21 Vaxdesign Corp IMMUNOTHERAPY COMPOSITIONS, METHODS FOR PREPARING AND USING THE SAME
US20060008466A1 (en) * 2004-07-07 2006-01-12 University Of Saskatchewan Methods for treating and preventing microbial infections
EP1824976A4 (en) 2004-11-12 2008-07-09 Univ British Columbia ANTIMICROBIAL PEPTIDES
PL2061886T3 (pl) 2006-08-21 2014-10-31 Univ British Columbia Małe kationowe peptydy immunomodulujące
US9102754B2 (en) * 2007-06-28 2015-08-11 University Of Saskatchewan Immunomodulatory compositions and methods for treating disease with modified host defense peptides
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
CA2737352C (en) * 2008-10-16 2017-06-27 University Of Saskatchewan Combination adjuvant formulation

Also Published As

Publication number Publication date
CA2737352C (en) 2017-06-27
AU2009304552B2 (en) 2015-02-19
US20140248313A1 (en) 2014-09-04
DK2344522T3 (en) 2016-04-18
EP2344522B1 (en) 2016-01-27
US9061001B2 (en) 2015-06-23
WO2010043039A1 (en) 2010-04-22
HUE028497T2 (en) 2016-12-28
AU2009304552A2 (en) 2011-07-07
NZ601345A (en) 2014-05-30
US20100239611A1 (en) 2010-09-23
EP2344522A1 (en) 2011-07-20
US9408908B2 (en) 2016-08-09
BRPI0920240B1 (pt) 2021-01-19
AU2009304552A1 (en) 2010-04-22
BRPI0920240B8 (pt) 2021-05-25
NZ591925A (en) 2012-09-28
CA2737352A1 (en) 2010-04-22
EP2344522A4 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
BRPI0920240A2 (pt) formulação de adjuvante de combinação
BRPI0921327A2 (pt) Combinação de herbicida-protetor
DK2634232T3 (da) Sammensætninger
BRPI0922730A2 (pt) formulação de anticorpo
BRPI0907376A2 (pt) Fotobiorretador
DE602009000234D1 (de) msignals
BRPI0909644A2 (pt) dispositivo de foto-epilação
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
UA18940S (uk) Шоколад
BRPI0814188A2 (pt) Formulações
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI1009465A2 (pt) Formulação
BRPI0907522A2 (pt) biarlamidas
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
BRPI0922728A2 (pt) combinação de herbicida-antídoto
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909637A2 (pt) 2-aminoquinolinas
AT507449A3 (de) Dämmstoffbefestiger
BRPI0921578A2 (pt) vacinas unitemporais
BRPI0920833A2 (pt) preparação de benzonorborbenos

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/196.226 DE 16/10/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL.

B12F Appeal: other appeals
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF